Buparlisib (BKM120)

For research use only. Not for use in humans.

目录号：S2247 别名： NVP-BKM120 中文名称：布帕尼西

CAS No. 944396-07-0

Buparlisib (BKM120, NVP-BKM120) 是一种选择性 PI3K 抑制剂，在无细胞试验中作用于p110α/β/δ/γ的IC50分别为 52 nM/166 nM/116 nM/262 nM。对 VPS34，mTOR，DNAPK 的作用效果下降，而对 PI4Kβ几乎没有活性。Buparlisib 可诱导凋亡。Phase 2。

规格

价格

库存

购买数量

10mM (1mL in DMSO)	RMB 2227.95	现货
5mg	RMB 1400.12	现货
10mg	RMB 2607.65	现货
50mg	RMB 7928.28	现货
大包装	有超大折扣

大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的Buparlisib (BKM120)发表文献178篇：

Cell, 2020, 25;181(7):1596-1611.e27.

PubMed: 32559461 ( click the link to review the publication )

Cancer Cell, 2020, 37(2):183-199

PubMed: 31978326 ( click the link to review the publication )

Nat Immunol, 2020, 21(4):442-454

PubMed: 32152508 ( click the link to review the publication )

Science, 2019, 364(6441)

PubMed: 31097636 ( click the link to review the publication )

Cancer Cell, 2018, 34(6):922-938

PubMed: 30537514 ( click the link to review the publication )

Cancer Cell, 2018, 33(1):91-107

PubMed: 29316436 ( click the link to review the publication )

Cell, 2017, 161(4):803-16

PubMed: 25913192 ( click the link to review the publication )

Cancer Discov, 2017, 7(9):1018-1029

PubMed: 28619981 ( click the link to review the publication )

Nature, 2016, 529(7586):413-417

PubMed: 26735014 ( click the link to review the publication )

Nat Med, 2015, 10.1038/nm.3855

PubMed: 25939062 ( click the link to review the publication )

Nat Med, 2015, 21(9):1038-47

PubMed: 26301689 ( click the link to review the publication )

Cancer Discov, 2014, 4(1):69-79

PubMed: 24265152 ( click the link to review the publication )

Cancer Discov, 2013, 4(2):232-45

PubMed: 24356096 ( click the link to review the publication )

Cancer Discov, 2013, 4(2):186-99

PubMed: 24302555 ( click the link to review the publication )

Cell, 2012, 27;149(3):656-70.

PubMed: 22541435 ( click the link to review the publication )

Nat Med, 2012, 18(6):892-901

PubMed: 22610277 ( click the link to review the publication )

Cancer Cell, 2012, 21(2):155-67

PubMed: 22340590 ( click the link to review the publication )

Genome Med, 2020, 18;12(1):17

PubMed: 32070411 ( click the link to review the publication )

Cell Rep, 2020, 31(12):107800

PubMed: 32579927 ( click the link to review the publication )

Cell Rep, 2020, 33(1):108221

PubMed: 33027668 ( click the link to review the publication )

Sci Signal, 2020, 3;13(621) pii: eaax2364

PubMed: 32127496 ( click the link to review the publication )

Cancers (Basel), 2020, 12(9)E2500

PubMed: 32899250 ( click the link to review the publication )

Br J Cancer, 2020, 10.1038/s41416-020-01074-2

PubMed: 32963347 ( click the link to review the publication )

Mol Cancer Res, 2020, 11

PubMed: 32161139 ( click the link to review the publication )
Sci Rep, 2020, 10(1):16208

PubMed: 33004905 ( click the link to review the publication )

Front Neurosci, 2020, 2;14:223

PubMed: 32300287 ( click the link to review the publication )

Eur J Pharmacol, 2020, 870:172821

PubMed: 31770526 ( click the link to review the publication )

Cell Biol Int, 2020, 10.1002/cbin.11322

PubMed: 32068318 ( click the link to review the publication )

Turk J Haematol, 2020, 37(3):167-176

PubMed: 32160736 ( click the link to review the publication )

BMC Cancer, 2020, 20(1):724

PubMed: 32758183 ( click the link to review the publication )

FASEB Bioadv, 2020, 2(2):126-144

PubMed: 32123862 ( click the link to review the publication )

NPJ Breast Cancer, 2020, 6:30

PubMed: 32715085 ( click the link to review the publication )

Mol Oncol, 2020, 10.1002/1878-0261.12673

PubMed: 32191822 ( click the link to review the publication )

Cancer, 2020, 10.1002/cncr.33071

PubMed: 32767682 ( click the link to review the publication )

Small GTPases, 2020, 10.1080/21541248

PubMed: 32043900 ( click the link to review the publication )

Nat Cell Biol, 2019, 21(2):226-237

PubMed: 30692625 ( click the link to review the publication )

Nat Commun, 2019, 10(1):259

PubMed: 30651547 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2910

PubMed: 31266951 ( click the link to review the publication )

Nat Commun, 2019, 10(1):1515

PubMed: 30944303 ( click the link to review the publication )

J Thorac Oncol, 2019, 14(6):1061-1076

PubMed: 30825612 ( click the link to review the publication )

Leukemia, 2019, 10.1038/s41375-019-0556-z

PubMed: 31462739 ( click the link to review the publication )

Cell Syst, 2019, 8(2):97-108

PubMed: 30797775 ( click the link to review the publication )

Theranostics, 2019, 9(8):2380-2394

PubMed: 31149050 ( click the link to review the publication )

Cell Rep, 2019, 27(1):294-306

PubMed: 30943409 ( click the link to review the publication )

Cell Rep, 2019, 27(2):631-647

PubMed: 30970263 ( click the link to review the publication )

Cell Rep, 2019, 28(9):2317-2330

PubMed: 31461649 ( click the link to review the publication )

Cell Death Differ, 2019, 10.1038/s41418-019-0422-6

PubMed: 31570855 ( click the link to review the publication )

Cancer Lett, 2019, 466:23-34

PubMed: 31521695 ( click the link to review the publication )
Cancers (Basel), 2019, 11(2)

PubMed: 30736342 ( click the link to review the publication )

Mol Ther Oncolytics, 2019, 13:58-66

PubMed: 31016228 ( click the link to review the publication )

Cancer Discov, 2019, 9(9):1306-1323

PubMed: 31217297 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(4):834-844

PubMed: 30787173 ( click the link to review the publication )

Aging (Albany NY), 2019, 11(18):7780-7795

PubMed: 31545294 ( click the link to review the publication )

J Cell Physiol, 2019, 234(7):10907-10917

PubMed: 30536897 ( click the link to review the publication )

Front Oncol, 2019, 0.87569444444

PubMed: 31428587 ( click the link to review the publication )

Front Oncol, 2019, 9:1119

PubMed: 31750239 ( click the link to review the publication )

Eur J Immunol, 2019, doi: 101002/eji201948241

PubMed: 31621069 ( click the link to review the publication )

Mol Pharmacol, 2019, 95(5):528-536

PubMed: 30858165 ( click the link to review the publication )

Prostate, 2019, 79(11):1347-1359

PubMed: 31228231 ( click the link to review the publication )

Chem Biol Interact, 2019, 302:101-107

PubMed: 30703376 ( click the link to review the publication )

Eur J Pharmacol, 2019, 842:89-98

PubMed: 30401630 ( click the link to review the publication )

Biochem Biophys Res Commun, 2019, 513(3):546-552

PubMed: 30981504 ( click the link to review the publication )

Leuk Lymphoma, 2019, 10.1080/10428194.2019.1594211

PubMed: 30947576 ( click the link to review the publication )

Int J Hematol, 2019, 110(2):213-227

PubMed: 31129802 ( click the link to review the publication )

Oncol Lett, 2019, 17(3-:3151-3162

PubMed: 30867745 ( click the link to review the publication )

NPJ Breast Cancer, 2019, 05:31

PubMed: 31552290 ( click the link to review the publication )

Nat Biomed Eng, 2018, 2(8):578-588

PubMed: 31015631 ( click the link to review the publication )

Nat Biomed Eng, 2018, 2(4):239-253

PubMed: 30936439 ( click the link to review the publication )

Nat Protoc, 2018, 13(12):2827-2843

PubMed: 30382243 ( click the link to review the publication )

Nat Commun, 2018, 9(1):4550

PubMed: 30382095 ( click the link to review the publication )

Nat Commun, 2018, 9(1):1357

PubMed: 29636477 ( click the link to review the publication )

EMBO Mol Med, 2018, 10(5)

PubMed: 29650805 ( click the link to review the publication )
Cancer Res, 2018, 78(8):2000-2013

PubMed: 29437705 ( click the link to review the publication )

Cancer Res, 2018, 78(9):2383-2395

PubMed: 29440171 ( click the link to review the publication )

NPJ Genom Med, 2018, 3:15

PubMed: 29951225 ( click the link to review the publication )

Cancer Res, 2018, 78(14):4007-4021

PubMed: 29760046 ( click the link to review the publication )

Cell Rep, 2018, 24(8):2155-2166

PubMed: 30134175 ( click the link to review the publication )

Cell Rep, 2018, 24(2):463-478

PubMed: 29996106 ( click the link to review the publication )

Elife, 2018, 7e33718

PubMed: 30475204 ( click the link to review the publication )

Int J Cancer, 2018, 143(5):1188-1201

PubMed: 29582409 ( click the link to review the publication )

Int J Cancer, 2018, 142(9):1926-1937

PubMed: 29210065 ( click the link to review the publication )

Oncogene, 2018, 37(3):363-376

PubMed: 28945225 ( click the link to review the publication )

Cancer Lett, 2018, 439:56-65

PubMed: 30243708 ( click the link to review the publication )

Sci Signal, 2018,

PubMed: 29535262 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(2):347-354

PubMed: 28958992 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(4):599-609

PubMed: 29330285 ( click the link to review the publication )

Oncol Rep, 2018, 40(6):3223-3234

PubMed: 30272286 ( click the link to review the publication )

Oncol Rep, 2018, 40(1):479-487

PubMed: 29767248 ( click the link to review the publication )

PLoS One, 2018, 13(2):e0191890

PubMed: 29389967 ( click the link to review the publication )

Oncol Lett, 2018, 15(3):3321-3328

PubMed: 29435074 ( click the link to review the publication )

Oncotarget, 2018, 9(56):30869-30882

PubMed: 30112114 ( click the link to review the publication )

J Exp Med, 2018, 215(1):159-175

PubMed: 29141866 ( click the link to review the publication )

Mol Cell, 2017, 67(3):512-527

PubMed: 28757207 ( click the link to review the publication )

Mol Cell, 2017, 65(6):999-1013

PubMed: 28306514 ( click the link to review the publication )

Nat Commun, 2017, 8:15623

PubMed: 28585535 ( click the link to review the publication )

Nat Commun, 2017, 8;8:15617

PubMed: 28593995 ( click the link to review the publication )
Nat Commun, 2017, 8:15021

PubMed: 28443643 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1278

PubMed: 29097657 ( click the link to review the publication )

Dev Cell, 2017, 43(6):673-688

PubMed: 29103956 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2017, 114(41):E8628-E8636

PubMed: 28973876 ( click the link to review the publication )

Cancer Res, 2017, 77(16):4448-4459

PubMed: 28652248 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(4):729-738

PubMed: 28119490 ( click the link to review the publication )

Mol Cancer Ther, 2017, 10.1158/1535-7163

PubMed: 28119489 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(9):1779-1790

PubMed: 28619753 ( click the link to review the publication )

Mol Cell Proteomics, 2017, 16(10):1864-1888

PubMed: 28794006 ( click the link to review the publication )

BMC Cancer, 2017,

PubMed: 28806950 ( click the link to review the publication )

SLAS Discov, 2017, 22(8):974-984

PubMed: 28644734 ( click the link to review the publication )

Oncotarget, 2017,

PubMed: 28977994 ( click the link to review the publication )

Oncotarget, 2017, 8(32):52474-52487

PubMed: 28881745 ( click the link to review the publication )

Cell Stem Cell, 2017, 20(2):233-246

PubMed: 27989769 ( click the link to review the publication )

Oncotarget, 2017, 8(13):21806-21817

PubMed: 28423521 ( click the link to review the publication )

Oncotarget, 2017,

PubMed: 29137323 ( click the link to review the publication )

Oncotarget, 2017, 8(4):6608-6622

PubMed: 28036259 ( click the link to review the publication )

Oncotarget, 2017, 8(44):76935-76948

PubMed: 29100359 ( click the link to review the publication )

Nat Cell Biol, 2016, 18(12):1324-1335

PubMed: 27870828 ( click the link to review the publication )

Blood, 2016, 127(10):1325-35

PubMed: 26668133 ( click the link to review the publication )

Genome Biol, 2016, 17:80

PubMed: 27139883 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(3):644-56.

PubMed: 26224873 ( click the link to review the publication )

PLoS Biol, 2016, 14(11):e1002581

PubMed: 27880766 ( click the link to review the publication )

Cancer Res, 2016, 76(24):7168-7180

PubMed: 27913436 ( click the link to review the publication )
Cell Rep, 2016,

PubMed: 27292631 ( click the link to review the publication )

J Hematol Oncol, 2016, 9(1):113

PubMed: 27765055 ( click the link to review the publication )

Cancer Discov, 2016, 6(10):1134-1147

PubMed: 27604488 ( click the link to review the publication )

J Transl Med, 2016, 14:56

PubMed: 26912358 ( click the link to review the publication )

Int J Biochem Cell Biol, 2016, 79:308-317

PubMed: 27599915 ( click the link to review the publication )

PLoS One, 2016, 11(1):e0147682

PubMed: 26821351 ( click the link to review the publication )

PLoS One, 2016, 10.1371/journal

PubMed: 27055253 ( click the link to review the publication )

Oncotarget, 2016, 7(41):67277-67287

PubMed: 27572309 ( click the link to review the publication )

Nature, 2016, 529(7586):413-417

PubMed: 26735014 ( click the link to review the publication )

Oncotarget, 2016, 7(26):40398-40417

PubMed: 27259258 ( click the link to review the publication )

Oncotarget, 2016,

PubMed: 27153554 ( click the link to review the publication )

Sci Rep, 2016, 6:20189

PubMed: 26846842 ( click the link to review the publication )

Oncotarget, 2016, 7(45):72608-72621

PubMed: 27579615 ( click the link to review the publication )

J Clin Invest, 2015, 10.1172/JCI78018

PubMed: 25798617 ( click the link to review the publication )

J Clin Invest, 2015, 125(12):4559-71

PubMed: 26529251 ( click the link to review the publication )

Genes Dev, 2015, 29(16):1677-82

PubMed: 26272820 ( click the link to review the publication )

Cancer Res, 2015, 75(14):2851-62

PubMed: 25977330 ( click the link to review the publication )

Oncogene, 2015, 10.1038/onc.2015.173

PubMed: 25982275 ( click the link to review the publication )

Glia, 2015, 63(10):1850-9

PubMed: 25944104 ( click the link to review the publication )

Biomed Pharmacother, 2015, 75:40-50

PubMed: 26463630 ( click the link to review the publication )

Acta Pharmacol Sin, 2015, 10.1038/aps.2015.4

PubMed: 25864651 ( click the link to review the publication )

Cell Signal, 2015, 27(12):2389-400

PubMed: 26363466 ( click the link to review the publication )

Exp Cell Res, 2015, 332(2):223-35

PubMed: 25704758 ( click the link to review the publication )

Exp Cell Res, 2015, 332(2):223-35

PubMed: ( click the link to review the publication )
Int J Biochem Cell Biol, 2015, 60C:34-42

PubMed: 25578563 ( click the link to review the publication )

Int Immunopharmacol, 2015, 28(1):675-85

PubMed: 26256696 ( click the link to review the publication )

PLoS One, 2015, 10(9):e0133610

PubMed: 26402468 ( click the link to review the publication )

PLoS One, 2015, 10(4):e0123410

PubMed: 25844720 ( click the link to review the publication )

Immunol Res, 2015, 10.1007/s12026-015-8648-y

PubMed: 25869396 ( click the link to review the publication )

Oncotarget, 2015, 6(31):31792-804

PubMed: 26397139 ( click the link to review the publication )

Crit Rev Oncol Hematol, 2015,

PubMed: 26253360 ( click the link to review the publication )

J Clin Invest, 2014, 124(12):5490-502

PubMed: 25401474 ( click the link to review the publication )

J Clin Invest, 2014, 124(11):4737-52

PubMed: 25250573 ( click the link to review the publication )

J Exp Med, 2014, 211(13):2497-2505

PubMed: 25488980 ( click the link to review the publication )

Cancer Res, 2014, 10.1158/0008-5472.CAN-14-1392

PubMed: 25297634 ( click the link to review the publication )

Cell Rep, 2014, 8(5):1265-70

PubMed: 25176649 ( click the link to review the publication )

Oncogene, 2014, 10.1038/onc.2014.328

PubMed: 25284585 ( click the link to review the publication )

PLoS Pathog, 2014, 10(6):e1004196

PubMed: 24945378 ( click the link to review the publication )

Breast Cancer Res, 2014, 16(1):R9

PubMed: 24451154 ( click the link to review the publication )

Breast Cancer Res, 2014, 16(4):406

PubMed: 25103565 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1134

PubMed: 24651437 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1013

PubMed: 24457957 ( click the link to review the publication )

Mol Cancer Res, 2014, 12(10):1520-31

PubMed: 25103499 ( click the link to review the publication )

J Biol Chem, 2014, 289(33):22785-97

PubMed: 24982421 ( click the link to review the publication )

PLoS One, 2014, 9(10):e108780

PubMed: 25360799 ( click the link to review the publication )

PLoS One, 2014, 9(7):e101969

PubMed: 25003333 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 10.1016/j.bbrc.2014.09.129

PubMed: 25285632 ( click the link to review the publication )

Oncotarget, 2014, 5(14):5295-303

PubMed: 24979463 ( click the link to review the publication )
Assay Drug Dev Technol, 2014, 12(9-10):514-26

PubMed: 25506801 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(21):5940-51

PubMed: 23918606 ( click the link to review the publication )

Cancer Res, 2013, 73(17):5459-72

PubMed: 23796563 ( click the link to review the publication )

Oncogene, 2013, 10.1038/onc.2013.509

PubMed: 24292683 ( click the link to review the publication )

Breast Cancer Res, 2013, 15(4):R55

PubMed: 23844554 ( click the link to review the publication )

Cell Commun Signal, 2013, 11(1):3

PubMed: 23311350 ( click the link to review the publication )

Mol Cancer Res, 2013, 11(10):1269-78

PubMed: 23814023 ( click the link to review the publication )

BMC Cancer, 2013, 13:465

PubMed: 24103747 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2013, 71(5):1297-307

PubMed: 23479136 ( click the link to review the publication )

University Gattingen, 2013, Elisabeth Hand

PubMed: ( click the link to review the publication )

产品安全说明书

PI3K抑制剂选择性比较

生物活性

产品描述

特性

BKM120是可用于口服的生物有效的PI3K抑制剂。

靶点

p110α ^[1] (Cell-free assay)	p110δ ^[1] (Cell-free assay)	p110β ^[1] (Cell-free assay)	p110γ ^[1] (Cell-free assay)	Vps34 ^[1] (Cell-free assay)	点击更多
52 nM	116 nM	166 nM	262 nM	2.4 μM	点击更多

体外研究

BKM120作用于解除PI3K调节的细胞系，包括A2780, U87MG, MCF7和DU145时，具有抗增殖活性，GI50为0.1-0.7 nM。^[1] BKM120诱导多发性骨髓瘤细胞(ARP1, ARK, MM.1S, MM1.R和U266)凋亡，导致G1期细胞增多，S期细胞减少。BKM120诱导CD138+原代MM 细胞凋亡，且作用于CD138−基质细胞时毒性较低。BKM120可引起BimS的上调和XIAP的下调。^[2]BKM120作用于人类胃癌细胞系，降低mTOR下游信号，具有抗增殖活性。BKM120作用于KRAS突变的胃癌细胞系，可以增强p-ERK或 p-STAT3。BKM120 和STAT3阻断剂联用, 作用于含突变KRAS的细胞，诱导凋亡，具有协同效应，但是作用于KRAS野生型细胞没有这种效果。^[3]BKM120主要通过Aurora B激酶调节有丝分裂崩坏。^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
MCF7	M3XNbGN6fG:2b4jpZ{BCe3OjeR?=		NGT0RVQ4OiCq	NH3UO3ZFVVOR	NYPO[mpYS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUOINzDj[YxteyCneIDy[ZN{cW6pIGDJN2tidHCqYTDFOVQ2UyCvdYThcpQhf2m2aDDHTVUxKG:oIECuNFAxOTV6IN88US=>	MXKyOFkxODJ4Nh?=
DU145	NHf4cXhEgXSxdH;4bYMhSXO\|YYm=		NGXxWJY4OiCq	NUToR3Y1TE2VTx?=	MofpR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gSHUyPDViY3XscJMh\XiycnXzd4lv\yCOS1KxJI12fGGwdDD3bZRpKEeLNUCgc4YhOC5yMEC0N\|Uh\|ryP	MYOyOFkxODJ4Nh?=
A2780	NWjYZYE3S3m2b4TvfIlkKEG\|c3H5		NX\B[oJWPzJiaB?=	M4nR[2ROW09?	NEnOXHZEgXSxdH;4bYNqfHliYXfhbY5{fCCSVFXOMYRm\mmlaXXueEBpfW2jbjDBNlc5OCClZXzsd{B4cXSqIFfJOVAhd2ZiMD6wNFA3OzVizszN	NXHNbmZOOjR7MECyOlY>
U87MG	MlfYR5l1d3SxeHnjJGF{e2G7		NIHVU2w4OiCq	MUDEUXNQ	MV7DfZRwfG:6aXPpeJkh[WejaX7zeEBRXEWQLXTl[olkcWWwdDDoeY1idiCXOEfNS{Bk\WyuczD3bZRpKEeLNUCgc4YhOC5yMEC2PVgh\|ryP	Mn3GNlQ6ODB{Nk[=
A2780	M3nXTGZ2dmO2aX;uJGF{e2G7		MnK4NUBp	NGLHRlJFVVOR	MYjJcohq[mm2aX;uJI9nKFCLM1utcYVlcWG2ZXSgRWtVKFOnckS3N{BxcG:\|cHjvdplt[XSrb36ge4l1cCCHQ{WwJI9nKDBwMEW1JO69VQ>?	NVjvOVVtOjR7MECyOlY>
DU145	NHz0fYFHfW6ldHnvckBCe3OjeR?=		Mn\ZNUBp	MY\EUXNQ	MkPqTY5pcWKrdHnvckBw\iCSSUPLMY1m\GmjdHXkJGFMXCCVZYK0O\|MheGixc4Doc5J6dGG2aX;uJIlvKGi3bXHuJGRWOTR3IHPlcIx{KGijcnLvdolv\yCOS1KxJI12fGG2aX;uJJdqfGhiRVO1NEBw\iByLkC3N{DPxE1?	NHnFS\|czPDlyMEK2Oi=>
A2780	NVOyUG1CTnWwY4Tpc44hSXO\|YYm=		NU[xW2p[OSCq	NGD4VVZFVVOR	M{L3SmlvcGmkaYTpc44hd2ZiUFmzT{1u\WSrYYTl[EBCU1RiU3XyOFc{KHCqb4PwbI9zgWyjdHnvckBqdiCSVFXOMYRm\mmlaXXueEBpfW2jbjDBNlc5OCClZXzsd{B4cXSqIFXDOVAhd2ZiMD6wO\|Qh\|ryP	NFWye44zPDlyMEK2Oi=>
MCF7	NYCwO2ZlTnWwY4Tpc44hSXO\|YYm=		NIqzOVIyKGh?	MoHNSG1UVw>?	MYLJcohq[mm2aX;uJI9nKFCLM1vhcJBp[SCHNUS1T{BufXSjboStcYVlcWG2ZXSgRWtVKFOnckS3N{BxcG:\|cHjvdplt[XSrb36ge4l1cCCHQ{WwJI9nKDBwMTFOwG0>	MnPENlQ6ODB{Nk[=
U87MG	M3HuSWZ2dmO2aX;uJGF{e2G7		M1SwW\|EhcA>?	Ml\nSG1UVw>?	M3fZOWlvcGmkaYTpc44hd2ZiUFmzT{1u\WSrYYTl[EBCU1RiU3XyOFc{KHCqb4PwbI9zgWyjdHnvckBqdiCSVFXOMYRm\mmlaXXueEBpfW2jbjDVPFdOTyClZXzsd{B4cXSqIFXDOVAhd2ZiMD6xN{DPxE1?	NV71dnl[OjR7MECyOlY>
A2780	NFnacWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NFGwVZo4OiCq	M3L1dGROW09?	NHfmcnhGSzVyPUCuOVIh\|ryP	MVqyOFkxODJ4Nh?=
SKMES-1	MVXDfZRwfG:6aXOgRZN{[Xl?	M1LGdFEh\|ryP	M{HMR\|czKGh?		MXvJcoR2[2W\|IHPlcIwh\GWjdHi=	M{PY[VI3ODF\|M{G4
H596	M2KwU2Z2dmO2aX;uJGF{e2G7	MonKNUDPxE1?			MYrJcZBicXK\|IHPlcIwhdWmpcnH0bY9v	MUKyOlAyOzNzOB?=
HCC2450	Ml[2SpVv[3Srb36gRZN{[Xl?	Mli2NUDPxE1?			MYTJcZBicXK\|IHPlcIwhcW64YYPpc44>	MlrwNlYxOTN\|MUi=
A549	M{TNOGZ2dmO2aX;uJGF{e2G7	MnT0OVAxKG6P	MXe0PEBp	Ml7aSG1UVw>?	MUDJcohq[mm2czDBb5Qh[WO2aY\heIlwdg>?	NFTpVo4zPTl\|N{K5PS=>
A549	Mnm2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmDWNUDPxE1?	MWW3NkBp	MnzvSG1UVw>?	MnLUTY5pcWKrdIOgZ4VtdCCpcn;3eIg>	MVOyOVk{PzJ7OR?=
H522	NFfa[4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEnvUGEyKM7:TR?=	MXe3NkBp	Mn\kSG1UVw>?	Mmi1TY5pcWKrdIOgZ4VtdCCpcn;3eIg>	NGOxTVUzPTl\|N{K5PS=>
LNCaP	M3;aXWZ2dmO2aX;uJGF{e2G7	NUjTXFFMOSEQvF2=			NWDUc4Z[W3WycILld5NmeyCyLVHLWEBt\X[nbIO=	M4jGfVI2OzZyN{m5
LNCaP95	MmL2SpVv[3Srb36gRZN{[Xl?	MmnMNUDPxE1?			M1rGb3N2eHC{ZYPz[ZMheC2DS2SgcIV3\Wy\|	MXWyOVM3ODd7OR?=
HCT-15	NH6zc3dCeG:2b4Ppd{BCe3OjeR?=	NEfuN3AyOCEQvF2=	MmfCOFghcA>?	MWfEUXNQ	Mk\0TY5lfWOnczDhdI9xfG:\|aYOgbY4hUEOWLUG1JINmdGy\|IHjhdoJwfXKrbnegVGlMO0ODIHjveJNxd3RibYX0ZZRqd25?	NHjFRWYzPTF3MkK0OS=>
HCT-116	NFzIVItCeG:2b4Ppd{BCe3OjeR?=	MVyxNEDPxE1?	NFPNfXM1QCCq	M1PM[2ROW09?	M4L5W2lv\HWlZYOgZZBweHSxc3nzJIlvKEiFVD2xNVYh[2WubIOgbIFz[m:3cnnu[{BRUUt\|Q1GgbI91e3CxdDDteZRifGmxbh?=	M3voSlI2OTV{MkS1
NCI-H460	NH3pdndCeG:2b4Ppd{BCe3OjeR?=	MmfXNVAh\|ryP	MkLUOFghcA>?	Mmf4SG1UVw>?	NGjmdZVKdmS3Y3XzJIFxd3C2b4Ppd{BqdiCQQ1mtTFQ3OCClZXzsd{Bp[XKkb4XybY5oKFCLS{PDRUBpd3S\|cH;0JI12fGG2aX;u	MmHXNlUyPTJ{NEW=
SKOV-3	MYfBdI91d3OrczDBd5NigQ>?	MWGxNEDPxE1?	MoPaOFghcA>?	MnuzSG1UVw>?	NXHFSGlKUW6mdXPld{BieG:ydH;zbZMhcW5iU1vPWk0{KGOnbHzzJIhiemKxdYLpcochWEmNM1PBJIhwfHOyb4SgcZV1[XSrb36=	MV[yOVE2OjJ2NR?=
BSY-1	NVrtbVJ2SXCxdH;zbZMhSXO\|YYm=	NV6zPWR6OTBizszN	M3XwblQ5KGh?	NYGx[45FTE2VTx?=	M4Trd2lv\HWlZYOgZZBweHSxc3nzJIlvKEKVWT2xJINmdGy\|IHjhdoJwfXKrbnegVGlMO0ODIHjveJNxd3RibYX0ZZRqd25?	MnzZNlUyPTJ{NEW=
MKN-1	NUfxTZBISXCxdH;zbZMhSXO\|YYm=	NFXsfG4yOCEQvF2=	MUK0PEBp	M1KzOmROW09?	M{TWZ2lv\HWlZYOgZZBweHSxc3nzJIlvKE2NTj2xJINmdGy\|IHjhdoJwfXKrbnegVGlMO0ODIHjveJNxd3RibYX0ZZRqd25?	MoPPNlUyPTJ{NEW=
NCI-H522	NXPPc5JSSXCxdH;zbZMhSXO\|YYm=	NEf5OnMyOCEQvF2=	MVe0PEBp	MWHEUXNQ	NYfHdWxZUW6mdXPld{BieG:ydH;zbZM>	MUWyOVE2OjJ2NR?=
OVCAR-3	MV3BdI91d3OrczDBd5NigQ>?	MkjUNVAh\|ryP	NXz6fWNZPDhiaB?=	MYDEUXNQ	NXP2R5BjUW6mdXPld{BieG:ydH;zbZM>	MXiyOVE2OjJ2NR?=
HBC-5	MXXBdI91d3OrczDBd5NigQ>?	M3vNV\|ExKM7:TR?=	NWfWcHd5PDhiaB?=	NXjYWpRXTE2VTx?=	MVfJcoR2[2W\|IHHwc5B1d3Orcx?=	MlPSNlUyPTJ{NEW=
RXF-631L	MoHTRZBwfG:\|aYOgRZN{[Xl?	MlzRNVAh\|ryP	MV:0PEBp	M3uxd2ROW09?	M{TXOGlv\HWlZYOgZZBweHSxc3nz	M3LjNVI2OTV{MkS1
MKN-45	NX7QXIYxSXCxdH;zbZMhSXO\|YYm=	MVGxNEDPxE1?	MYm0PEBp	NUL3PYdETE2VTx?=	M4mwd2lv\HWlZYOgZZBweHSxc3nz	MWKyOVE2OjJ2NR?=
BON-1	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmO4OVAxKG6P	M4LWS\|ExKGR?	M2DXU2ROW09?	NGrXSIdKdmirYnn0d{Bk\WyuIHfyc5d1cA>?	M{P5c\|I2ODJ4Mkmy
BON-1	NI[5UFdHfW6ldHnvckBCe3OjeR?=	NGWwW\|I2ODBibl2=	M1LhbVQhcA>?	NWja[nNHTE2VTx?=	MX7Jcohq[mm2czDwbI9{eGixconsZZRqd25ib3[gRWtVKGG2IGTodlMxQCCjbnSgV4VzPDd\|	M3[3PFI2ODJ4Mkmy
QGP-1	M{G4RmZ2dmO2aX;uJGF{e2G7	Mnj6OVAxKG6P	NEXaeXg1KGh?	M4PzR2ROW09?	Mm\TTY5pcWKrdIOgdIhwe3Cqb4L5cIF1cW:wIH;mJGFMXCCjdDDUbJI{ODhiYX7kJHNmejR5Mx?=	NFTsdYozPTB{NkK5Ni=>
Huh7	MoTuSpVv[3Srb36gRZN{[Xl?	MUixJO69VQ>?	NYD3cll5OSCq	NGLVeY9FVVOR	NELjXJRKdmirYnn0d{BxcG:\|cHjvdplt[XSrb36gc4YhSUuWIHH0JHNmejR5NB?=	NXjrW4JwOjVyMES0NFM>
BNL	NVraNmV6TnWwY4Tpc44hSXO\|YYm=	M3n3U\|Eh\|ryP	NWDwTJdWOSCq	NYDmNG1KTE2VTx?=	NXzLWId3UW6qaXLpeJMheGixc4Doc5J6dGG2aX;uJI9nKFN4	NHXyfoMzPTByNESwNy=>
MDA-MB-175	Mn[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlnyNUDPxE1?	Mm[xOUBl	M1XvZmROW09?	MnTJTWM2ODxzIN88US=>	NIK5cIczPDh5OUe5Oi=>
MDA-MB-134	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkXBNUDPxE1?	NFnDOWo2KGR?	MWPEUXNQ	MlzKTWM2ODxzIN88US=>	NFzxXogzPDh5OUe5Oi=>
HCC1500	NEfvPXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnnsNUDPxE1?	NUjpfYtOPSCm	NYjTd2U4TE2VTx?=	NFX4Z4ZKSzVyPEGg{txO	NW\TUW5DOjR6N{m3PVY>
EFM-19	NEe4eoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkX2NUDPxE1?	MV[1JIQ>	M3Tub2ROW09?	MkLITWM2ODxzIN88US=>	M3m3WFI1QDd7N{m2
ZR-75-30	M1LTTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIjGXoMyKM7:TR?=	MnLjOUBl	MofNSG1UVw>?	MVrJR\|UxRDFizszN	NFP6b3YzPDh5OUe5Oi=>
MDA-MB-361	MlHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFXtWnoyKM7:TR?=	M{nDclUh\A>?	MoLNSG1UVw>?	MXLJR\|UxRDFizszN	MnLwNlQ5Pzl5OU[=
T-47D	NIr4c5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVOxJO69VQ>?	MWC1JIQ>	NX3qSXN3TE2VTx?=	M3\ldWlEPTB:MTFOwG0>	MkW3NlQ5Pzl5OU[=
SK-BR-3	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlfkNUDPxE1?	MmrROUBl	M1jo[WROW09?	M33vRWlEPTB:MTFOwG0>	M2TpUlI1QDd7N{m2
UACC-732	MnrIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2nVVFEh\|ryP	NYK1WWVmPSCm	NFH3cFlFVVOR	NHfK[pZKSzVyPEGg{txO	M3nqcVI1QDd7N{m2
BT-474	NF7sW2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1TGUVEh\|ryP	MkHwOUBl	MVTEUXNQ	MWTJR\|UxRDFizszN	NVzveFhGOjR6N{m3PVY>
HCC202	NVHkWXRxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV\TZXU6OSEQvF2=	M3fZS\|Uh\A>?	NV\WSHl6TE2VTx?=	M4LuUWlEPTB:MTFOwG0>	M2T1TVI1QDd7N{m2
MCF7	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVyxJO69VQ>?	NGDJOGw2KGR?	NXXZW3ZZTE2VTx?=	MYHJR\|UxRDFizszN	NWHlPVgyOjR6N{m3PVY>
MDA-MB-415	NH:5UXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWSxJO69VQ>?	MnzHOUBl	NH;1dnZFVVOR	NH;Od\|ZKSzVyPEGg{txO	NVPqXoduOjR6N{m3PVY>
MDA-MB-453	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWDnNo5VOSEQvF2=	NW\ZcZJbPSCm	NUWxcotUTE2VTx?=	MVLJR\|UxRDFizszN	NUDNTnBtOjR6N{m3PVY>
ZR-75-1	Ml7VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mne2NUDPxE1?	M2n0eVUh\A>?	MWfEUXNQ	NHHScoNKSzVyPEGg{txO	MoHaNlQ5Pzl5OU[=
HCC38	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYK4Z5BHOSEQvF2=	M4n2N\|Uh\A>?	NYXNOHVnTE2VTx?=	M1zWXGlEPTB:MTFOwG0>	NGLiRWEzPDh5OUe5Oi=>
HCC1419	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXqxJO69VQ>?	NXToVHppPSCm	NXW5Z4dCTE2VTx?=	M13UWWlEPTB:MTFOwG0>	NFrkPIEzPDh5OUe5Oi=>
UACC-812	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWOxJO69VQ>?	NH\3V2I2KGR?	M2\KVWROW09?	M3uyW2lEPTB:MTFOwG0>	M2PaO\|I1QDd7N{m2
HCC1187	M33xU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHnwPYsyKM7:TR?=	MY[1JIQ>	Mn3ISG1UVw>?	MonpTWM2ODxzIN88US=>	M{nlUlI1QDd7N{m2
KPL-1	NF\DNHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2DQNlEh\|ryP	MoDwOUBl	M2\2dWROW09?	NUnjd\|RPUUN3MEyxJO69VQ>?	MYmyOFg4QTd7Nh?=
SUM-225	NXvzdmF4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{[yfVEh\|ryP	NH24T3k2KGR?	NGfDPIVFVVOR	NIj0dYRKSzVyPEGg{txO	NIDNXYszPDh5OUe5Oi=>
EFM-192A	Mnv5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkjhNUDPxE1?	NE\1OGo2KGR?	NEm5UopFVVOR	NYXjOnJbUUN3MEyxJO69VQ>?	M1HHblI1QDd7N{m2
JIMT-1	NVvNOIJMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn:3NUDPxE1?	NFPKNnY2KGR?	MUTEUXNQ	M13YfmlEPTB:MTFOwG0>	MYiyOFg4QTd7Nh?=
HCC1143	MkLwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUSxJO69VQ>?	NFXFb2I2KGR?	NI\afHBFVVOR	NG\a[XpKSzVyPEGg{txO	M4LOWVI1QDd7N{m2
HCC2218	M1nwemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlTUNUDPxE1?	Mm\KOUBl	MVLEUXNQ	MlXITWM2ODxzIN88US=>	NUnrXFBiOjR6N{m3PVY>
MDA-MB-468	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXexJO69VQ>?	Mn3LOUBl	NF\lb2tFVVOR	NG\qXpZKSzVyPEGg{txO	M4HTTlI1QDd7N{m2
BT-20	M4TDOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1qxOFEh\|ryP	M4DMe\|Uh\A>?	MWTEUXNQ	NIHEN5BKSzVyPEGg{txO	NHe3bVIzPDh5OUe5Oi=>
MDA-MB-435	NXGwVoZiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHvGWlAyKM7:TR?=	NVnLV3BLPSCm	NWLBR3JHTE2VTx?=	M2O0[WlEPTB:MTFOwG0>	M2rLe\|I1QDd7N{m2
BT-549	M1LWV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFHOfZQyKM7:TR?=	M{XWc\|Uh\A>?	MnjBSG1UVw>?	MUfJR\|UxRDFizszN	NUTkOIFtOjR6N{m3PVY>
HCC1806	M1WyNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoW4NUDPxE1?	NVrYR4ZWPSCm	M{[we2ROW09?	NWfLOXpiUUN3MEyxJO69VQ>?	NGfpUWIzPDh5OUe5Oi=>
HCC1937	NXXJcHNrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXjscWZFOSEQvF2=	M{TobVUh\A>?	NX7iUJJkTE2VTx?=	NULR[4F5UUN3MEyxJO69VQ>?	M3\lOVI1QDd7N{m2
Hs578T	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3rlNlEh\|ryP	MXy1JIQ>	NYGx[3M6TE2VTx?=	MWXJR\|UxRDFizszN	NHzzbFgzPDh5OUe5Oi=>
LN18	NGHleFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1O0PFIxKM7:TR?=	MVW3NkBp	NHLvbVdFVVOR	NGjzfGNKSzVyPEWg{txO	MXeyOFc1OTB5NB?=
LN229	Mlv6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NISweIkzOCEQvF2=	NXroN4s3PzJiaB?=	MWrEUXNQ	MnfMTWM2ODx3IN88US=>	MnHYNlQ4PDFyN{S=
LNZ308	Mm\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkfONlAh\|ryP	Mn;EO\|IhcA>?	Mme2SG1UVw>?	M{G5eWlEPTB:NTFOwG0>	NYXRcVA4OjR5NEGwO\|Q>
T98G	NUnQdo1UT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWi3eWFXOjBizszN	NF3KWFI4OiCq	Ml7vSG1UVw>?	NHXaOmVKSzVyPEWg{txO	MljENlQ4PDFyN{S=
U87	NH\ye2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3nPelIxKM7:TR?=	M4DRVVczKGh?	M2KyNmROW09?	NHzmO5JKSzVyPEWg{txO	M17mV\|I1PzRzMEe0
LN18	MUnGeY5kfGmxbjDBd5NigQ>?	MkS5OUDPxE1?	NUCzd4JJOjRiaB?=	MnzNSG1UVw>?	MlzvTY5pcWKrdIOgdIhwe3Cqb4L5cIF1cW:wIH;mJGFMXA>?	MWiyOFc1OTB5NB?=
LNZ308	MYLGeY5kfGmxbjDBd5NigQ>?	NHvXeGc2KM7:TR?=	NXrZR5gxOjRiaB?=	NV7ucGJoTE2VTx?=	MV7Jcohq[mm2czDwbI9{eGixconsZZRqd25ib3[gRWtV	NUDQV\|ZnOjR5NEGwO\|Q>
Saos-2	MYXGeY5kfGmxbjDBd5NigQ>?	M1rkW\|UxKM7:TR?=	Mm\wOFghcA>?		NG[0eFdKdmirYnn0d{Bk\WyuIHnueoF{cW:w	Mm\ONlQ4Ojd4NkC=
MG-63	NEi5dHFHfW6ldHnvckBCe3OjeR?=	NXnqWGhVPTBizszN	Mn7JOFghcA>?		M{XtT2lvcGmkaYTzJINmdGxiaX72ZZNqd25?	M2L4SlI1PzJ5Nk[w
SJSA-1	M4XXRWZ2dmO2aX;uJGF{e2G7	MVG1NEDPxE1?	Ml\COFghcA>?		MYjJcohq[mm2czDj[YxtKGmwdnHzbY9v	MWCyOFczPzZ4MB?=
Saos-2	M32zVGZ2dmO2aX;uJGF{e2G7	M4XWOVUxKM7:TR?=	M1nnSFQ5KGh?		NGj4d5ZKdmirYnn0d{Bu[XS{aYigcYV1[Wyub4Dyc5RmcW6jc3WtNkBmgHC{ZYPzbY9v	MkLSNlQ4Ojd4NkC=
MG-63	MUXGeY5kfGmxbjDBd5NigQ>?	M4jYO\|UxKM7:TR?=	M4HtOlQ5KGh?		MWrJcohq[mm2czDtZZRzcXhibXX0ZYxtd3C{b4TlbY5ie2VvMjDlfJBz\XO\|aX;u	M3PyZVI1PzJ5Nk[w
SJSA-1	MnrCSpVv[3Srb36gRZN{[Xl?	MVq1NEDPxE1?	MkjHOFghcA>?		NV70OGFuUW6qaXLpeJMhdWG2cnn4JI1mfGGubH;wdo91\WmwYYPlMVIh\XiycnXzd4lwdg>?	M2\hSFI1PzJ5Nk[w
Saos-2	NU\LWFB[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NED6OoM2OCEQvF2=	NIjuTlI1QCCq		M4HO[GlvcGmkaYTzJINmdGxidnnhZoltcXS7	MYGyOFczPzZ4MB?=
MG-63	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXHKS5NOPTBizszN	MlTSOFghcA>?		NXn2PJV1UW6qaXLpeJMh[2WubDD2bYFjcWyrdIm=	MUWyOFczPzZ4MB?=
SJSA-1	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFXwfXA2OCEQvF2=	M1vHflQ5KGh?		NW\pSIxZUW6qaXLpeJMh[2WubDD2bYFjcWyrdIm=	NFXYXnozPDd{N{[2NC=>
FaDu	MkWzSpVv[3Srb36gRZN{[Xl?	MYq1JO69VQ>?	NIrlR2YzPCCq	MUjEUXNQ	M37WfHJm\HWlZYOgc5h6\2WwIHPvcpN2dXC2aX;u	MmLTNlQ3OzFzNEe=
EMT6	MXXGeY5kfGmxbjDBd5NigQ>?	MWe1JO69VQ>?	MX2yOEBp	MXLEUXNQ	M{f5cnJm\HWlZYOgc5h6\2WwIHPvcpN2dXC2aX;u	MYWyOFY{OTF2Nx?=
HCT116	NWnkNIpkTnWwY4Tpc44hSXO\|YYm=	M3vaTFUh\|ryP	MYSyOEBp	NWHqeoNvTE2VTx?=	NXnhXpFuWmWmdXPld{BwgHmpZX6gZ49ve3WvcITpc44>	MnHONlQ3OzFzNEe=
U87	MV3GeY5kfGmxbjDBd5NigQ>?	NYr2S5N1PSEQvF2=	MmTxNlQhcA>?	MoDrSG1UVw>?	Mm\KVoVlfWOnczDvfJlo\W5iY3;ud5VueHSrb36=	NW\MVWJ4OjR4M{GxOFc>
GBM	NUi0TWZTSXCxcITvd4l{KEG\|c3H5	NVS1cYpnOs7:TR?=	MVK0PIg>	MkTiSG1UVw>?	MlzKbY5lfWOnZDDobYdp\XJibHX2[Yx{KG:oIHHwc5B1d3OrczygZY5lKGSnY4LlZZNm\CClZXzsJJZq[WKrbHn0fS=>	NFv6UpozPDVyMES5Ni=>
BON	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3iw[\|EuPc7:TR?=	MoT1O\|Jp		NWTud3Br\GWlcnXhd4V{KGOnbHygdJJwdGmoZYLheIlwdg>?	MmnLNlQ1PDN3MkO=
BON	MX3BdI9xfG:\|aYOgRZN{[Xl?	M4jZd\|EuPc7:TR?=	NIDPNJozPGh?		NG\4VYVqdmO{ZXHz[ZMh[XCxcITvd4l{	NIr6OG0zPDR2M{WyNy=>
H1975	MmfVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFrwWnUxNjNvOT62{txO	MWi3Nog>	NY\xeoRYTE2VTx?=	NI\jd3RKSzVyPUGuN\|g2\|ryP	NXT5OnlpOjR\|M{e4OFY>
H1975	MXHBdI9xfG:\|aYOgRZN{[Xl?	MnLJNu69VQ>?	MXWyOIg>	M3fYeWROW09?	NYLaXIYycW6lcnXhd4V{KGGyb4D0c5NqeyC{YYTlJJNq\26rZnnjZY51dHl?	NYjiO3VrOjR\|M{e4OFY>
T-ALL	NWnS[\|ViSXCxcITvd4l{KEG\|c3H5	M1TSWoJmfHenZX6gNU41KGGwZDC1MlMhdU1iYYSgNlRpKGGwZDCwMlkh[W6mIEWuOUBuVSCjdDC0PIghcW5iZHnm[oVz\W62IHPlcIwhdGmwZR?=	NUO1V4lJOjRib4KgOFhp	NFT2OXZFVVOR	MWjh[oZm[3S\|IITo[UBRUTONIIDheIh4[XliaX6gWE1CVExiY3XscEBtcW6ncx?=	MVqyOFMyODd\|Nh?=
BCR-ABL	NFznPZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M17XUVAvOjVvMUFOwG0>	MXe0[C=>		NF31RWd{cWewaX\pZ4FvfGy7IHnubIljcXRiY3XscEBxem:uaX\ldoF1cW:w	MoHHNlQzPDR4MUK=
LC-1/SQSF	NYfQZXZMTnWwY4Tpc44hSXO\|YYm=	NU\D[5lpO87:TR?=	NIH5bHMzPGh?	NIr0SIZFVVOR	MoL4[IVkemWjc3WgUnJHOiCycn;0[YlvKGyndnXs	NELKOHAzOzl6MEC5Ny=>
Primary CLL cells	NELPSpZCeG:ydH;zbZMhSXO\|YYm=	MlrQNU0yOM7:TR?=	Ml\NOFhp		NYqwTFdUcW6mdXPld{BieG:ydH;zbZMhcW5iQ1zMJINmdGy\|IHnu[IVx\W6mZX70JI9nKHC{b3fuc5N1cWNibXHyb4Vzew>?	NGnNOXczOzh3MEiwOy=>
Primary CLL cells	MU\LbY5ie2ViQYPzZZk>	MknyNu69VQ>?	MU[zNI1qdg>?		MkS2[IVkemWjc3XkJHBKO0tiYXP0bZZqfHl?	NG\GVHkzOzh3MEiwOy=>
Primary CLL cells	MnziR5l1d3SxeHnjJGF{e2G7	MofjNu69VQ>?	NYnMW3BPOjSq		NYX2dnh3cW6mdXPld{Bk\WyuIHP5eI91d3irY3n0fS=>	NVPVT2lZOjN6NUC4NFc>
human NSCLC cell lines	MmHFRZBweHSxc3nzJGF{e2G7	MYOwMlEzPS12zszN	MmjBNlRp	NX[1Vmk2TE2VTx?=	M1XrPGlEPTC\|IILhcodmeyCocn;tJFAvPC1{zszN	M2frO\|I{PTZ{NEey
human HCC cell lines	NHjJ[2RE\WyuII\pZYJqdGm2eTDhd5NigQ>?	MV6wMlAxPS1zzszN	Mn7xOFhp		MYHJR\|UxRTIQvF2=	MVKyN\|Q5QTl7OR?=
Huh7	NV;BeG1pU2mwYYPlJGF{e2G7	MWqx{txO	MYq0PIg>		NXXFWIpPe2mpbnpvsKFk[W62bImgdoVlfWOnczDwbI9{eGixconsZZRqd25ib3[gRYt1	MmDNNlM1QDl7OUm=
SK-HEP1	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYDrfnI{OS1{MN88US=>	MWm3Nog>	MX\EUXNQ	MYrJR\|Ux97zeMd88US=>	MUKyN\|Q4QTF\|Nh?=
786-0	NVjIfpc6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M13FTVEuOjEQvF2=	NUjmUm1xPzKq	MWTEUXNQ	Ml7xTWM2OO,:nEJOwG0>	Mmq3NlM1PzlzM{[=
JVM2	M2LGOmN6fG:2b4jpZ4l1gSCjc4PhfS=>	MWiwMlIuOjEQvF2=	MlzBO\|Jp	MoqzSG1UVw>?	Mmf3TWM2OD1yLkpOwG0>	NEjP[lczOzJ\|OE[zPS=>
EHEB	NIX6N5FEgXSxdH;4bYNqfHliYYPzZZk>	NITKXmMxNjJvMkFOwG0>	NH\Ke3M4Omh?	Mo[1SG1UVw>?	MmDLTWM2OD1yLkhOwG0>	MmnYNlMzOzh4M{m=
MEC2	NYDlXll2S3m2b4TvfIlkcXS7IHHzd4F6	Ml7xNE4zNTJyzszN	MoTzO\|Jp	MlXwSG1UVw>?	MnzHTWM2OD1yLkhOwG0>	M3TlRVI{OjN6NkO5
primary B-CLL lymphocytes	MV;BdI9xfG:\|aYOgRZN{[Xl?	MUTJR\|UxKG[xcjDlZYNpKHC{aX3hdpkh[2WubDDsbY5m	NXW0UlVoOjSq	M3nnXmROW09?	MoTMTWM2OO,:nEROwG0h\m:{IHHscEBx[XSrZX70dy=>	Mny0NlMzOzh4M{m=
primary B-CLL lymphocytes	NVvoR3FWU2mwYYPlJGF{e2G7	NVLqXJJvUUN3MDDmc5Ih\WGlaDDwdolu[XK7IHPlcIwhdGmwZR?=	NHnaXnUzPGh?		M4fkeIlvcGmkaYTzJJA4OFN4SzCmJFRGNUKSMTDlfJBz\XO\|aX;u	NHnafoQzOzJ\|OE[zPS=>
human NSCLC	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnrHNE42NTMQvF2=	NUjORZd1PzKq		NUjDdFl3UUN3ME2x{txO	M4D5OlIzPzhzM{mz
human NSCLC	M{jqUGtqdmG\|ZTDBd5NigQ>?	MkLTNe69VQ>?	NGDVToczPGh?		NE\IdopqdmirYnn0d{B1cGViQXv0M41VV1Jic3nncoFtcW6pIIDheIh4[XliYYSgN4gh[W[2ZYKgeJJm[XSvZX70	M4XOSVIzPzhzM{mz
Y1 cell line	NUTHfnFET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3rWV\|AvOc7:TT:x{txO	M{njOFI1cA>?	M3z0WWROW09?	MVvpcohq[mm2czC2NQ+9jSClZXzsJJZq[WKrbHn0fUBqdiCPeXOtV4N1ei22cnHud4Zm[3SnZDDj[Yxtew>?	NVSyPGFsOjJ4OUK5NFQ>
PIK3CA-mutant MCF7	NVrNUVVYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX\HTVUxRTF4MNMxPVFvVe,:jFzEOVA:QThywsGyO\|NvVQ>?	MXS3Nog>		MX;HTVUxRTF4MNMxPVFvVe,:jFzEOVA:QThywsGyO\|NvVQ>?	NUXVUYl5OjJ4NUO5Olc>
PIK3CA-mutant MCF7	M4nOPGtqdmG\|ZTDBd5NigQ>?	MVLJR\|UxRTFzNNMxN45O	NXm3[3ZNPzKq		NV36WWdKUUN3ME2xNVTDuTOwTTDpckBz\WS3Y3nu[{BCc3RicHjvd5Bpd3K7bHH0bY9vKGyndnXsdy=>	NEjofWMzOjZ3M{m2Oy=>
MCF7-myr-Akt	M4CzZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUnhdmlST0l3ME2yPVnDuTZ6bl5vwKxNTDVy78{eNVAtODBybl2=	NHKySHI4Omh?		NYDNToJmT0l3ME2yPVnDuTZ6bl5vwKxNTDVy78{eNVAtODBybl2=	NYLST5RsOjJ4NUO5Olc>
colon cancer cell lines	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVuwMVEx\|ryP	NHXadIg4Omh?	MVzEUXNQ	Mmf0TWM2OD1zzszN	MVSyNlU1Ozh3Nx?=
gastric cancer cell lines	M3zJOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYTyclgyOC1zMN88US=>	M4DkV\|czcA>?	NFjyWoNFVVOR	MXnJR\|UxRTJvNd88US=>	MkDZNlI2PDN6NUe=
HCT-116/HT-29/MKN-45	M2DpfGFxd3C2b4Ppd{BCe3OjeR?=	NVzpUYo1Os7:TR?=	NGDZR481QGh?		M3\NXJNpcW[2IHnuJGczKHCqYYPl	MWCyNlU1Ozh3Nx?=
HT-29 and HCT-116	MYDDZZNx[XOnIHHzd4F6	NInpVpU2\|ryP	M2juelI1cA>?		NVTzVmV7cW6mdXPld{Bk[XOyYYPlJIFkfGm4aYT5	MXeyNlU1Ozh3Nx?=
MM cell lines	Mn7qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIPhWY4yOM7:TR?=	NV3KRmVFOjSq	NXTyVnJpTE2VTx?=	NXzRZ2pFUUN3MDD2ZZJq\XNiYX3vcoch\GmoZnXy[Y51KGOnbHygcIlv\XNiaX6geIlu\SCjbnSg[I9{\SCmZYDlcoRmdmOn	NX;vN3dtOjJ{MEe0PFU>
ARP-1	NE\a[5pCeG:ydH;zbZMhSXO\|YYm=	NVv1OIpOOTEQvF2=	MoPrNlRp	M3jsPGROW09?	M1q5d4lv\HWlZYOgUW0h[2WubDDhdI9xfG:\|aYOgeIhzd3WpaDDjZZNx[XOnIHHjeIl3[XSrb36=	NVTXN5J5OjJ{MEe0PFU>
SNU-601	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MUm3Nog>	NHHqT4ZFVVOR	NF;iTVNKSzVyPUCuPFE3yrFyLkC2N:69VQ>?	M2TtRVIzOTV7OEG0
SNU-1	NHro[WxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M{fQblczcA>?	NXXnd3RpTE2VTx?=	MmTjTWM2OD1zLkC4NuKyOC5yMklOwG0>	NITkb5IzOjF3OUixOC=>
SNU-668	MkXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NUXTNVRsPzKq	M4fLRWROW09?	MU\JR\|UxRTFwNUe5xtExNjB5NN88US=>	M{\udVIzOTV7OEG0
AGS	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MoHrO\|Jp	MmLMSG1UVw>?	NFzwUHlKSzVyPUGuO\|E1yrFyLkGxO:69VQ>?	M3nmcVIzOTV7OEG0
SNU-216	NHnSc\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MkD4O\|Jp	MoPWSG1UVw>?	NHHkbJhKSzVyPUKuOlkzyrFyLkC4Nu69VQ>?	NEXsZ3MzOjF3OUixOC=>
SNU-5	Mln5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M1Xxb\|czcA>?	MWDEUXNQ	MWHJR\|UxRTFwM{WxxtExNjB7Md88US=>	NG\kW5EzOjF3OUixOC=>
SNU-638	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NX7FNHFHPzKq	NGPCVIxFVVOR	NFPsd5lKSzVyPUKuNlgzyrFyLkC1N:69VQ>?	M4TrTVIzOTV7OEG0
SNU-16	MoHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NXzvOY5GPzKq	M1\ReGROW09?	MmPhTWM2OD1zLkW3N:KyOC5yMEJOwG0>	MXmyNlE2QThzNB?=
SNU-484	NFPvT5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MoLOO\|Jp	NWC4R3hUTE2VTx?=	NXu0c2xmUUN3ME2xMlczQMLzMD6wOFXPxE1?	MmDNNlIyPTl6MUS=
SNU-620	NGDLW3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NXfmSZFDPzKq	NUm5SnhsTE2VTx?=	MmDnTWM2OD1{LkmzPeKyOC5yMEJOwG0>	MVWyNlE2QThzNB?=
SNU-719	MmqxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M3LMe\|czcA>?	M4HORmROW09?	NGSzPWxKSzVyPUOuNFM4yrFyLkCzNu69VQ>?	NX7zRm9nOjJzNUm4NVQ>
glioma cell lines	NWO5b\|FCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NIe5Um44Omh?		MVnJR\|UxRTFvMt88US=>	MWOyNlA3PTB6MB?=
U87	NWDYNGl3SXCxcITvd4l{KEG\|c3H5	M4jRdlLPxE1?	MnruO\|Jp		MUXpcoR2[2W\|IHPlcIwh[XCxcITvd4l{KGGwZDDjcIVifmWmIGDBVnAh[W6mIHPhd5Bie2VvMx?=	Mmn0NlIxPjVyOEC=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-AKT (T308) / p-AKT (S473) / AKT; PubMed: 27283525 J Neurooncol Left western blots showing levels of pAkt (T308), pAkt (S473) and total Akt in U87 cells exposed to buparlisib for 72 h. Right densitometric assessment of western blots, showing relative changes in phosphorylation. p-FOXO3a (S253) / FOXO3a; PubMed: 28036259 Oncotarget Cells were treated with 0.5 μM BKM120 for 24 h and cell lysates were immunoblotted with the indicated antibodies. Actin was used as the loading control. Nuclear NF-κB p65 / NF-κB p65; PubMed: 26673665 Cell Death Dis Western blots show BKM120 downregulating pAKT, nuclear NF-κB p65 and total NF-κB p65 in MDR and their parental cells. β-actin was used as a loading control for pAKT, AKT and total NF-κB p65. Lamin B was used as a loading control for nuclear NF-κB p65. p-ERK / ERK / LC3; PubMed: 27572309 Oncotarget The indicated cell lines were exposed to different concentrations of BKM120 as indicated for 8 h A. or with 2 μM BKM120 for the indicated times B. The cells were then harvested for preparation of whole-cell protein lysates and subsequent Western blot analysis to detect the given proteins. p-STAT3 / STAT3 / p-ERK / ERK / p-S6; PubMed: 29928341 Oncol Lett Western blot analysis of H460 and H2126 cell lysates using specific antibodies to phosphorylated or total proteins of STAT3, ERK1/2, AKT, S6 or GAPDH (loading control). The cells were treated with increasing concentrations of BKM120 for 24 h. p-MET / MET; PubMed: 29928341 Oncol Lett The expression of phosphorylated or total forms of MET protein was analyzed by western blotting.	27283525 28036259 26673665 27572309 29928341
Immunofluorescence	FOXO3a; PubMed: 28036259 Oncotarget Cells were cultured on coverslips to approximately 60% confluency and then treated with 1 μM BKM120 for an additional 24 h. Immunofluorescence staining was performed using an anti-FOXO3a antibody and the nuclei were stained with DAPI. Scale bar, 20 μm.	28036259
Growth inhibition assay	Cell viability; PubMed: 26673665 Cell Death Dis Dose-response curves were used to calculate the IC50 of BKM120 for MCs of MCF-7/A02 cells (upper) and CALDOX cells (lower).	26673665

体内研究

BKM120按30, 60, 或100 mg/kg剂量作用于A2780移植瘤，完全抑制pAKTser473。BKM120按 30和 60 mg/kg剂量作用于U87MG神经胶质瘤模型，显示抗癌活性。^[1]BKM120每天按5μM/kg剂量处理具有持久生命力的ARP1 SCID鼠模型，导致肿瘤体积和K链水平明显降低。^[2]

激酶实验：^[2]	- 合并 PI3K 生化实验(ATP 消耗实验): BKM120溶于DMSO中，按每孔1.25 µL直接加到黑色384孔板上。开始反应, 25 µL 10nM PI3K和5 µg/mL 1-α-磷酸肌醇(PI)加到实验 buffer (10 mM Tris pH 为7.5, 5 mM MgCl₂, 20 mM NaCl, 1 mM DTT，及0.05% CHAPS)，然后加到每孔中，随后在实验buffer中加入25 µL 2 µM ATP。反应进行直到50% ATP被消耗，然后加入25 µL KinaseGlo溶液终止反应。终止的反应温育5分钟，然后通过荧光测定残留的ATP。
细胞实验：^[1]	- 合并 Cell lines: A2780细胞 Concentrations: 0-6.6 μM Incubation Time: 3天 Method: A2780细胞培养在含10% FBS,L-谷氨酸,丙酮酸钠和抗生素的DMEM培养基上。细胞按每孔10³个细胞的密度接种在相同培养基上，温育3到5小时。稀释溶于20 mM DMSO中的BKM120。2 µL稀释的BKM120溶液加到细胞培养基上, (浓度为0-6.6 µM)。等体积(100 µL)溶液加到96孔板中，在37^oC下温育3天。使用Trilux读取荧光值而测定抑制细胞增殖的效果 (Only for Reference)
动物实验：^[1]	- 合并 Animal Models: 携带U87MG 和A2780移植瘤的雌性裸鼠 Dosages: ~60 mg/kg Administration: 每天口服处理 (Only for Reference)

参考文献

[4] Koul D, et al. Clin Cancer Res, 2012, 18(1), 184-195.

- 合并

溶解度 (25°C)

体外	DMSO	82 mg/mL (199.8 mM)
	Ethanol	2 mg/mL (4.87 mM)
	Water	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 5% DMSO+30% PEG 300+ddH2O	15mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download Buparlisib (BKM120) SDF

分子量	410.39
化学式	C₁₈H₂₁F₃N₆O₂
CAS号	944396-07-0
储存条件	3年-20°C 粉状 2年-80°C 溶于溶剂
别名	NVP-BKM120

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % ddH₂O

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

临床试验信息 (data from https://clinicaltrials.gov, updated on 2020-09-01)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04338399	Not yet recruiting	Drug: Buparlisib & Paclitaxel	Head and Neck Cancer	Adlai Nortye Biopharma Co. Ltd.	July 31 2020	Phase 3
NCT02614508	Terminated	Drug: Buparlisib\|Drug: Ibrutinib\|Biological: Ofatumumab	Recurrent Chronic Lymphocytic Leukemia\|Recurrent Small Lymphocytic Lymphoma\|Refractory Chronic Lymphocytic Leukemia\|Refractory Small Lymphocytic Lymphoma	Emory University\|Novartis	January 2016	Phase 1
NCT01613677	Withdrawn	Drug: BKM120	Treatment for Metastatic or Locally Advanced Cervical Cancer	Novartis Pharmaceuticals\|Novartis	November 2015	Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

选择性强的PI3K抑制剂

CAL-101 (Idelalisib, GS-1101) : p110δ-selective, IC50=2.5 nM.
选择性强的PI3K抑制剂

TGX-221 : p110β-specific, IC50=5 nM.
活性最高的PI3K抑制剂

BEZ235 (NVP-BEZ235, Dactolisib) : p110α/γ/δ/β, IC50=4 nM/5 nM/7 nM/75 nM.
FDA批准的PI3K抑制剂

CAL-101 (Idelalisib, GS-1101) : Approved by FDA for Relapsed Chronic Lymphocytic Leukemia, Follicular Lymphoma and Small Lymphocytic Lymphoma.
最新的PI3K抑制剂

VS-5584 (SB2343) ^New : Potent and selective dual PI3K/mTOR inhibitor for mTOR, PI3Kα/β/δ/γ with IC50 of 3.4 nM and 2.6-21 nM, respectively.

研究领域

产品类型

定制您的化合物库

Buparlisib (BKM120)

客户使用Selleck生产的Buparlisib (BKM120)发表文献178篇：

产品安全说明书

PI3K抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download Buparlisib (BKM120) SDF

动物体内配方计算器 (澄清溶液)

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

临床试验信息 (data from https://clinicaltrials.gov, updated on 2020-09-01)

技术支持

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

相关PI3K产品